8-K: Sangamo Therapeutics Announces Genentech Deal, Positive Trial Results, and Q2 2024 Financials

Sangamo Therapeutics reported a significant licensing agreement with Genentech, positive Phase 3 trial results for a partnered hemophilia A therapy, and encouraging data from its Fabry disease program, alongside its second quarter 2024 financial results.

Summary

• Sangamo Therapeutics announced a global licensing agreement with Genentech for epigenetic regulation and capsid delivery technologies, expecting $50 million in near-term payments and up to $1.9 billion in potential milestones plus royalties.
• Pfizer reported positive topline results from the Phase 3 AFFINE trial for giroctocogene fitelparvovec, a hemophilia A gene therapy co-developed with Sangamo, with Sangamo eligible for up to $220 million in milestone payments and royalties.
• The Phase 1/2 STAAR study for Fabry disease gene therapy showed encouraging results, with 17 of 18 patients withdrawing from enzyme replacement therapy and preliminary evidence of improved kidney function.
• Sangamo's neurology-focused preclinical pipeline is progressing, with its STAC-BBB delivery capsid demonstrating industry-leading blood-brain barrier penetration in non-human primates.
• Second quarter 2024 net loss was $36.1 million, or $0.18 per share, compared to a net loss of $114.5 million, or $0.66 per share, for the same period in 2023.
• Revenues for the second quarter of 2024 were $0.3 million, down from $6.8 million in the same period of 2023, primarily due to the termination of collaboration agreements.
• Cash and cash equivalents were $27.8 million as of June 30, 2024, with an expected $50 million from the Genentech deal extending the cash runway into the first quarter of 2025.
• The company expects 2024 GAAP operating expenses to be between $150 million and $170 million, and non-GAAP operating expenses to be between $125 million and $145 million.

Sentiment

Score: 7

Explanation: The document presents a mix of positive developments, such as the Genentech deal and positive clinical trial results, alongside financial challenges, including reduced revenue and a low cash balance. The overall sentiment is cautiously optimistic, with significant potential but also considerable risks.

Positives

• The Genentech license agreement provides significant near-term funding and long-term potential through milestone payments and royalties.
• Positive Phase 3 results for the hemophilia A gene therapy validate Sangamo's technology and provide potential for future revenue.
• The Fabry disease program shows strong clinical data, with patients withdrawing from ERT and improved kidney function.
• The STAC-BBB capsid technology demonstrates significant potential for delivering therapies to the central nervous system.
• The company's net loss has significantly decreased year-over-year, indicating improved financial performance.
• The $50 million from the Genentech deal extends the cash runway into the first quarter of 2025.

Negatives

• Second quarter 2024 revenues decreased significantly to $0.3 million, down from $6.8 million in the same period of 2023, due to the termination of collaboration agreements.
• Cash and cash equivalents decreased to $27.8 million as of June 30, 2024, from $81.0 million at the end of 2023.
• The company is still operating at a loss, with a net loss of $36.1 million for the second quarter of 2024.

Risks

• The company's financial position remains precarious, with a need for additional funding to continue operations beyond the first quarter of 2025.
• There is a risk that the Genentech agreement could be terminated or that the expected benefits may not be realized.
• Clinical trial results may not be indicative of future results, and there is a risk that the therapeutic effects observed may not be durable.
• Regulatory approvals for product candidates are not guaranteed and are subject to unpredictable timelines.
• The company relies on collaborators, and there is a risk that they may not be able to secure additional collaborations.
• Macroeconomic factors and financial challenges could impact the company's operations and ability to conduct clinical trials.

Future Outlook

Sangamo expects the $50 million in near-term payments from the Genentech deal, combined with existing cash, to fund operations into the first quarter of 2025. The company anticipates continued progress in its neurology pipeline and potential for additional collaborations. They expect 2024 GAAP operating expenses to be between $150 million and $170 million, and non-GAAP operating expenses to be between $125 million and $145 million.

Management Comments

• Sandy Macrae, Chief Executive Officer of Sangamo, stated that the recent business development agreement with Genentech, positive topline results from the Phase 3 AFFINE trial, and encouraging Phase 1/2 data from the Fabry disease program have the potential to meaningfully extend the company's cash runway.
• Macrae also noted that the Genentech agreement reinforces the potential of Sangamo's gene editing and STAC-BBB capsid delivery platforms.

Industry Context

The announcement reflects a growing trend in the genomic medicine space, with increased focus on gene therapy and novel delivery methods for neurological diseases. The Genentech deal highlights the value of Sangamo's technology and the potential for partnerships in this sector. The positive results from the hemophilia A trial are also significant, as it is a competitive area with multiple companies developing gene therapies.

Comparison to Industry Standards

• Sangamo's STAC-BBB capsid delivery technology is described as demonstrating industry-leading blood-brain barrier penetration in non-human primates, suggesting a competitive advantage in CNS drug delivery compared to companies using traditional methods.
• The positive Phase 3 results for the hemophilia A gene therapy are comparable to other gene therapy programs in the space, such as BioMarin's Roctavian, which has also shown significant reductions in annualized bleeding rates.
• The Fabry disease program's results, with patients withdrawing from ERT and showing improved kidney function, are competitive with other therapies in development for this rare disease, such as enzyme replacement therapies and chaperone therapies.
• The financial results show a significant reduction in net loss compared to the previous year, but the company's cash position remains a concern, which is not uncommon for biotech companies in the development stage. Companies like CRISPR Therapeutics and Editas Medicine also face similar challenges in balancing R&D expenses with cash reserves.

Stakeholder Impact

• Shareholders will likely view the Genentech deal and positive clinical trial results favorably, but will also be concerned about the company's cash position.
• Employees may be encouraged by the company's progress but also aware of the financial challenges.
• Patients with hemophilia A and Fabry disease may benefit from the potential therapies in development.
• Potential collaborators may be interested in partnering with Sangamo given its technology and pipeline.

Next Steps

• Sangamo plans to participate in the Wells Fargo Healthcare Conference in September 2024.
• Sangamo plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference in September 2024.
• The company will continue to advance its neurology pipeline and seek additional collaborations.
• Pfizer will discuss the Phase 3 AFFINE trial data with regulatory authorities.
• Sangamo anticipates sharing updated clinical data from the Fabry disease program in the coming months.

Key Dates

Keywords

Genomic Medicine, Gene Therapy, Epigenetic Regulation, AAV Capsid Delivery, Neurology, Hemophilia A, Fabry Disease, STAC-BBB, Zinc Finger, MINT Platform